Fludarabine Phosphate

Fludarabine Phosphate

SCHEMBL3511

Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B

The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA5A P35218 1/20 1.00
NT5E P21589 6/20 0.82
P2RY1 P47900 8/20 0.73
P2RY11 Q96G91 5/20 0.73
DNPH1 O43598 1/20 0.73
PRKAB2 O43741 1/20 0.73
TRPM2 O94759 1/20 0.73
LDHA P00338 1/20 0.73
ADRB2 P07550 1/20 0.73
FBP1 P09467 1/20 0.73
SRC P12931 1/20 0.73
ADORA1 P30542 1/20 0.73
P2RY2 P41231 1/20 0.73
PRKAG1 P54619 1/20 0.73
PRKAA2 P54646 1/20 0.73
PDE4D Q08499 1/20 0.73
KCNH2 Q12809 1/20 0.73
PRKAA1 Q13131 1/20 0.73
PDE3A Q14432 1/20 0.73
SMN1; SMN2 Q16637 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fludarabine Phosphate SCHEMBL14565620 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL1650192 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL13046080 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL17541855 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL482449 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL23884975 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL899922 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL8401646 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL21173132 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1
Fludarabine Phosphate SCHEMBL30350656 1.00 CA5A (1.00) CA5ANT5EP2RY1P2RY11DNPH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 131070 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116209439-B Cereblon protein modulators Saint Jude Children's Research Hospital Ltd. (US) 2026-05-26 CN claimed
WO-2026102321-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS MARO BIO INC. (US) 2026-05-15 WO claimed
WO-2026102332-A1 NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF Blaze Bioscience, Inc. (US) 2026-05-15 WO claimed
US-20260132141-A1 PROTEIN PHOSPHATASE 2A ACTIVATORS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-14 US claimed
CN-122028920-A Method for treating hematological cancer 丹娜-法伯癌症研究院 2026-05-12 CN claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260109699-A1 AZOLE DERIVATIVES AS SHP2 INHIBITORS IRBM S.P.A. (IT) 2026-04-23 US claimed
US-20260102373-A1 LYMPH DIRECTING PRODRUGS MONASH UNIVERSITY (AU) 2026-04-16 US claimed
US-20260090997-A1 Lipid Nanoparticles Comprising Nucleic Acids Encoding Therapeutic Genes and Uses in Medical Methods UNIV EMORY (US) 2026-04-02 US claimed
US-20260076872-A1 POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME SIO2 MEDICAL PRODUCTS LLC (US) 2026-03-19 US claimed
EP-0393575-B1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent SEARLE & CO (US) 1994-03-16 EP claimed
EP-0359347-B1 COVALENTLY-LINKED COMPLEXES AND METHODS FOR ENHANCED CYTOTOXICITY AND IMAGING NEORX CORPORATION (US) 1992-12-23 EP claimed
EP-0487719-A4 PROCESS FOR THE PREPARATION OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-PHOSPHATE 1992-10-28 EP claimed
WO-1992009604-A1 6-AZIDO-2-FLUOROPURINE BERLEX BIOSCIENCES, INC. (US) 1992-06-11 WO claimed
EP-0487719-A1 PROCESS FOR THE PREPARATION OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-PHOSPHATE ASH STEVENS, INC. (US) 1992-06-03 EP claimed
US-5081110-A Method of killing sarcoma cells using fludarabine phosphate and ionizing radiation SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1992-01-14 US claimed
WO-1992000312-A1 PROCESS FOR THE PREPARATION OF 9-BETA-D-ARABINOFURANOSYL-2-FLUOROADENINE 5'-PHOSPHATE ASH STEVENS, INC. (US) 1992-01-09 WO claimed
EP-0393575-A1 Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent G.D. Searle & Co. (US) 1990-10-24 EP claimed
EP-0359347-A2 Covalently-linked complexes and methods for enhanced cytotoxicity and imaging NEORX CORPORATION (US) 1990-03-21 EP claimed
US-4357324-A Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1982-11-02 US claimed